Stage 4 kidney cancer is the most advanced form of the disease, meaning the tumor has either grown beyond the kidney’s surrounding tissue or spread to distant parts of the body. The five-year relative survival rate for kidney cancer that has reached distant organs is about 15% to 20%, though individual outcomes vary widely depending on where the cancer has spread and how well it responds to treatment.
What Makes It Stage 4
Kidney cancer staging follows the TNM system, which classifies tumors by their size and local invasion (T), lymph node involvement (N), and whether they’ve spread to distant sites (M). Stage 4 covers two distinct scenarios. In the first, the primary tumor has grown through the tough fibrous capsule surrounding the kidney, called Gerota’s fascia, and possibly into the adrenal gland that sits on top of it, but hasn’t necessarily spread elsewhere. In the second, the cancer has metastasized to distant organs, regardless of how large the original tumor is or whether lymph nodes are involved.
This distinction matters because a locally advanced tumor that hasn’t spread may be treated differently than one that has seeded cancer cells to the lungs or bones. Both are classified as stage 4, but they can carry very different prognoses.
Where Stage 4 Kidney Cancer Spreads
The lungs are by far the most common destination, involved in roughly 71% of metastatic cases. Lymph nodes are next at about 38%, followed by bone at 31%, the liver at 13%, the adrenal glands at 10%, and the brain at 8%. Less frequently, kidney cancer can show up in the pancreas, the lining around the lungs, the peritoneum, the spleen, the thyroid, or the bowel.
The location of metastases affects both symptoms and outlook. Bone metastases can cause deep, persistent pain and raise the risk of fractures. Brain metastases may trigger headaches, vision changes, or neurological symptoms. Lung metastases are sometimes found incidentally on imaging before they cause any noticeable breathing problems.
Symptoms at This Stage
Early kidney cancer often produces no symptoms at all, which is one reason it’s sometimes not caught until it has advanced. By stage 4, most people experience at least some of the following: blood in the urine, a noticeable lump or mass in the abdomen, persistent pain in the side or lower back, unexplained weight loss, loss of appetite, and anemia (which can cause fatigue, pallor, and shortness of breath).
Symptoms can also come from the metastatic sites rather than the kidney itself. Someone whose cancer has spread to bone may first notice back pain or a hip ache that doesn’t resolve. Liver involvement can cause jaundice or discomfort under the ribs on the right side. In some cases, kidney cancer triggers paraneoplastic effects, where the tumor releases substances that cause fever, elevated calcium levels, or changes in blood counts that seem unrelated to the kidneys.
How Doctors Assess Your Outlook
Not all stage 4 kidney cancer carries the same prognosis. Oncologists use a risk stratification system developed by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) to sort patients into risk categories. Three factors strongly predict outcomes: how much time passed between the original kidney cancer diagnosis and the start of systemic treatment (less than three years is worse), the patient’s overall physical functioning, and whether the cancer has reached the brain, liver, or bone.
Patients with none of these risk factors fall into a “very favorable” category, which applies to roughly 29% of cases. Those with one or more risk factors are classified as favorable, intermediate, or poor risk depending on how many factors are present. This classification guides treatment decisions and helps set realistic expectations. Someone in the very favorable group will generally respond better and live longer than someone in the poor-risk group, even though both technically have stage 4 disease.
Treatment With Immunotherapy
Treatment for stage 4 kidney cancer has changed dramatically over the past decade. The current standard for most patients starting treatment is a combination of two types of drugs: an immune checkpoint inhibitor paired with either another checkpoint inhibitor or a targeted therapy drug.
Checkpoint inhibitors work by removing the “brakes” that cancer cells put on the immune system, allowing the body’s own defenses to recognize and attack the tumor. One widely used combination pairs two checkpoint inhibitors together, which was approved for advanced kidney cancer in 2018. Another approach, approved in 2019, combines a single checkpoint inhibitor with a drug that blocks the blood vessel growth tumors need to survive. Both approaches have shown meaningful improvements in how long patients live and how long their disease stays under control compared to older treatments.
These combinations are typically given intravenously on a regular schedule, often every two to four weeks. Side effects can include fatigue, skin rashes, diarrhea, and inflammation in various organs as the immune system becomes more active. Most side effects are manageable, but some can be serious and require pausing or stopping treatment.
Targeted Therapy Drugs
Targeted therapies attack specific molecules that kidney cancer cells rely on to grow and build new blood vessels. The most common class works by blocking enzymes called tyrosine kinases. These drugs cut off both the tumor’s blood supply and the internal growth signals cancer cells use to multiply. They’re taken as daily pills, which many patients find more convenient than infusion-based treatments.
Targeted drugs are sometimes used alongside immunotherapy as a first treatment, or they may be given on their own if immunotherapy isn’t a good fit or stops working. A newer class of targeted drug takes a different approach by blocking a protein called HIF-2 alpha, which plays a central role in the most common type of kidney cancer (clear cell). One drug in this class received FDA approval in 2021 for a rare hereditary form of kidney cancer and was later approved in 2023 for advanced cases that had progressed through other treatments. Next-generation versions with improved characteristics are in clinical testing.
The Role of Surgery
Surgery to remove the cancerous kidney, called a nephrectomy, is sometimes performed even at stage 4 if the primary tumor is causing significant symptoms like bleeding or pain. In select cases where the cancer has spread to only one or a few sites, surgeons may remove both the kidney tumor and the metastases. This approach works best when the metastatic deposits are small and limited in number.
However, removing the kidney isn’t automatically beneficial when cancer has spread widely. The decision depends on the patient’s overall health, how many metastatic sites are involved, and whether systemic drug therapy is likely to be effective. For many patients, starting immunotherapy or targeted therapy first and considering surgery later (or not at all) is the more appropriate path.
Managing Symptoms From Metastases
Radiation therapy plays an important role in controlling symptoms caused by metastatic deposits, even though kidney cancer has traditionally been considered less sensitive to radiation than some other cancers. High-dose, precisely targeted radiation (sometimes called stereotactic body radiation) can shrink painful bone metastases or treat brain lesions. For bone metastases specifically, the pain relief from radiation doesn’t always correlate directly with tumor shrinkage, meaning patients may experience symptom improvement even before imaging shows the tumor responding.
Bone-strengthening medications can help reduce the risk of fractures when cancer has weakened the skeleton. For brain metastases, radiation (either whole-brain or targeted) is the primary approach, sometimes combined with surgery if only one or two lesions are present. Pain management, nutritional support, and physical rehabilitation are all part of comprehensive care at this stage, focused on maintaining quality of life alongside cancer-directed treatment.
Survival Rates in Context
The overall five-year survival rate of 15% to 20% for distant kidney cancer is a population-level average drawn from cases diagnosed between 2016 and 2022. That number reflects a mix of patients across all risk categories and treatment eras, including some who were diagnosed before the newest immunotherapy combinations became standard. Patients treated today with current first-line regimens often do better than those historical averages suggest, particularly those in favorable or very favorable risk groups.
Several factors push survival in a more positive direction: having metastases limited to the lungs (rather than the liver, bone, or brain), a longer gap between the initial kidney cancer diagnosis and the development of metastatic disease, good overall physical function, and a strong response to first-line immunotherapy. Some patients with stage 4 kidney cancer live for many years with ongoing treatment, and a small percentage achieve durable remissions where the cancer remains controlled indefinitely.